Trial Profile
A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post Infusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors ADMA Biologics; Biotest Pharmaceuticals
- 13 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2021 Planned End Date changed from 31 Mar 2021 to 30 Jun 2023.
- 14 Jun 2021 Planned primary completion date changed from 31 Mar 2021 to 31 Dec 2022.